Antitrust Health Care April 2018 Chronicle Vol. 32 / No. 3 In This Issue Editor’s Report E ective Advocacy Before FTC on Welcome to the third issue of the Chronicle for the ABA 2017-18 term. Health Care Deals In this issue, we are pleased to present an interview with Alexis Gilman, Interview with Alexis Gilman, former Assistant Director for Mergers IV at the Federal Trade Commission former Assistant Director for and current Partner at Crowell & Moring LLP. Chronicle editor Amanda Mergers IV at the Federal Trade Hamilton interviewed Gilman about best practices for advocating Commission and current Partner before the FTC on health care deals. Our second article discusses the at Crowell & Moring, by Chronicle implications of increased government focus on branded drug companies’ editor Amanda Hamilton, Associate refusals to sell samples of drugs subject to REMS programs to generic at Haug Partners fi rms and other forms of alleged REMS abuse. The third article provides a summary of recent congressional hearing activity related to antitrust issues in the health care sector. The FDA’s and FTC’s Increased Focus If there is a topic that you would like to see covered in a Committee program or if you have any other suggestions, please contact the on Generic Drug Committee Co-Chairs, Seth Silber (
[email protected]) or Leigh Oliver Competition Signals (
[email protected]). Enhanced Attention If you would like to submit an article for the Chronicle, please contact to REMS Issues Amanda Lewis (
[email protected]) or Anthony Swisher (Anthony.Swisher@ Heather Choi, William Lavery and squirepb.com).